Stereotactic Magnetic Resonance Guided Radiation Therapy

  • STATUS
    Recruiting
  • End date
    Jun 21, 2024
  • participants needed
    1000
  • sponsor
    Dana-Farber Cancer Institute
Send
Updated on 21 March 2021
See if I qualify
cancer
stereotactic body radiation therapy

Summary

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.

  • The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer.
  • Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

Description

This research study is a feasibility study, which means it is the first-time investigators at this institution are examining this type of MR-guided radiation to treat cancer.

The U.S. Food and Drug Administration (FDA) has approved this device as a treatment option for cancer.

In this research study, the investigators are hoping to determine if adjusting radiation treatments based on daily MRI has a feasible way to deliver radiation for participants with pancreatic, lung or renal cancer.

Details
Condition Malignant neoplasm of prostate, Pancreatic Cancer, Pulmonary Disease, urinary tract neoplasm, Malignant neoplasm of kidney, Nephropathy, Cancer, Prostatic disorder, Second Malignancy, Lung Neoplasm, Bronchial Neoplasm, synchronous neoplasms, Prostate Disorders, Liver Metastases, Kidney Disease (Pediatric), Cancer/Tumors, Prostate Cancer, Early, Recurrent, Ewing's Family Tumors, Liver Metastasis, Secondary Malignant Neoplasm of Liver, Hepatic Metastases, Cancer (Pediatric), Islet Ce417ll Cancer, Kidney Cancer, Lung Cancer, Prostate Cancer, Kidney Disease, Lung Disease, Neoplasms, Renal Cancer, Urologic Cancer, prostate carcinoma, adrenal metastases, second malignancies, cancer of the pancreas, cancer, renal, prostate cancers, pancreatic cancers, cancer, pancreatic, carcinoma lung, lung carcinoma, Oligoprogressive
Treatment MR-guided Linac
Clinical Study IdentifierNCT04115254
SponsorDana-Farber Cancer Institute
Last Modified on21 March 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Lung Neoplasm or Bronchial Neoplasm or Malignant neoplasm of kidney or Pancreatic Cancer or Lung Cancer?
Do you have any of these conditions: urinary tract neoplasm or Renal Cancer or Pancreatic Cancer or Urologic Cancer or Nephropathy or Bronchial Neoplasm or cancer, renal or pancreatic can...?
Do you have any of these conditions: carcinoma lung or Urologic Cancer or Pulmonary Disease or Kidney Cancer or cancer, pancreatic or Renal Cancer or Malignant neoplasm of kidney or Pancr...?
Do you have any of these conditions: Kidney Disease (Pediatric) or Lung Cancer or Prostatic disorder or Ewing's Family Tumors or Prostate Cancer or Cancer/Tumors or Prostate Cancer, Early...?
Do you have any of these conditions: Cancer or Pancreatic Cancer or Second Malignancy or pancreatic cancers or Cancer/Tumors or Nephropathy or Malignant neoplasm of prostate or Liver Meta...?
Participants must have a confirmed malignancy requiring stereotactic body radiation therapy. See specific disease site cohorts for more details
Tumor size 7cm
Age 18 years of older
ECOG performance status 2 (Karnofsky 60%, see Appendix A)
Ability to understand and the willingness to sign a written informed consent document
Specific eligibility requirements for each disease site with be covered in each specific cohort

Exclusion Criteria

Specific exclusion requirements for each disease site with be covered in each specific cohort
History of allergic reactions attributed to gadolinium-based IV contrast
\-- Note: If a patient will not receive contrast, this is not applicable
Pregnant women are excluded from this study
Severe claustrophobia or anxiety
Participants who cannot undergo an MRI
Clear my responses
Read more

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
stereotactic body radiation therapy

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note